ÂÜÀòÂÒÂ×

Gili Hart, Ph.D., has been a Director of Enlivex since 2014.

Dr. Hart previously held various positions in PROLOR Biotech and led the pre-clinical, clinical and pharmacological activities there from 2008 until her move to Mitoconix Bio, a biopharmaceutical company developing disease modifying therapies addressing unmet medical needs by improving mitochondrial health, where she serves as Chief Executive Officer.

Dr. Hart was a research fellow in the Immunology Department of Yale University in Connecticut from 2005 to 2007 and a research fellow at the Immunology Department of the Weizmann Institute of Science in Israel.

Dr. Hart received her Ph.D. with distinction from the Immunology Department of the Weizmann Institute of Science in immunology, and a M.S. degree in Biotechnology Engineering, summa cum laude, from the Technion Institute in Israel. Dr. Hart has published numerous papers and patents, in each case focusing on autoimmunity disease and immune system activation.